SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ArQule
ARQL 20.000.0%Jan 16 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (71)7/11/1997 2:23:00 PM
From: David S.   of 399
 
Richard my buddy, you are forgetting that yours truly bought Arql on the IPO and stated so earlier and also praised their technology. Given their wonderful technology platform, how long will it take before the Arql-SF collaboration comes up with protease inhibitors? In their presentations, Arql points out the incredible advantages of their approach vs. the "traditional" rational drug design method. What do you think. How much better is the ARQL approach vs. that of a firm such as say, Agouron? Having a medical background, I am interested in your opinion.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News